Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ZX008 (Fintepla/fenfluramine) in CDKL5 deficiency disorder with open-label extension
2023-506269-78-00Phase 3Authorised
- Sponsor
- Zogenix, Inc.
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of fenfluramine in CDKL5 deficiency disorder (CDD) (3 arms), sponsored by Zogenix, Inc. Planned start Jun 2023; status: authorised.
02
Drugs
fenfluramine
03
Conditions
CDKL5 deficiency disorder (CDD)
Beyond the preview
Go deeper on 2023-506269-78-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506269-78-00.